Investor Alert: Kaplan Fox Inves­ti­gates Helius Med­ical Tech­nolo­gies, Inc. (press release):

“NEW YORK, Feb. 7, 2019 /PRNewswire/ — Kaplan Fox & Kil­sheimer LLP has been inves­ti­gat­ing claims on behalf of investors of Helius Med­ical Tech­nologiues, Inc. (“Helius” or the “Com­pa­ny”) (Nas­daq: HSDT).

On Jan­u­ary 22, 2019, after the mar­ket opened, White Dia­mond Research pub­lished Read the rest of this entry »

6 Lit­tle-Known Star­tups Where Jeff Bezos Has Invest­ed Mil­lions (Inc.):

“Jeff Bezos is not only the world’s rich­est man, he’s also a very smart investor. That’s espe­cial­ly true when he invests in star­tups. Over the past few years, he’s put mon­ey into sev­er­al new com­pa­nies that turned out to be phe­nom­e­nal­ly suc­cess­ful, includ­ing Airbnb, Uber, Gen­er­al Assem­bly, Maker­Bot, and Look­out.

Where is Bezos putting his mon­ey these days? Into a hand­ful of com­pa­nies you’ve prob­a­bly nev­er heard of. But chances are you will, espe­cial­ly now Read the rest of this entry »

Bioethi­cists call for over­sight of poor­ly reg­u­lat­ed, con­sumer-grade neu­rotech­nol­o­gy prod­ucts (Med­ical News):

“The mar­ket­ing of direct-to-con­sumer “neu­rotech­nolo­gies” can be entic­ing: apps that diag­nose a men­tal state, and brain devices that improve cog­ni­tion or “read” one’s emo­tion­al state. How­ev­er, many of these increas­ing­ly pop­u­lar prod­ucts aren’t ful­ly sup­port­ed by sci­ence and have lit­tle to no reg­u­la­to­ry over­sight, which pos­es Read the rest of this entry »

“…When com­mit­ting to the Unit­ed Nations’ Sus­tain­able Devel­op­ment Goals in 2015, world lead­ers empha­sized the impor­tance of pro­mot­ing men­tal health and well-being world­wide. Yet three years lat­er, the sit­u­a­tion remains grim. Every year, 800,000 lives are lost due to sui­cide. In the Unit­ed States alone, Read the rest of this entry »

FDA grants break­through device des­ig­na­tion to Neu­raMetrix (press release):

“The U.S. Food and Drug Admin­is­tra­tion (FDA) has grant­ed Break­through Device des­ig­na­tion to the Neu­raMetrix brain health mon­i­tor­ing solu­tion. The des­ig­na­tion is grant­ed for devices “that pro­vide more effec­tive treat­ment or diag­no­sis of life-threat­en­ing or irre­versibly debil­i­tat­ing human dis­ease or con­di­tions”. The approved use is mon­i­tor­ing of Parkinson’s dis­ease (PD) Read the rest of this entry »